Redhill Biopharma Ltd
NASDAQ:RDHL
Redhill Biopharma Ltd
Operating Income
Redhill Biopharma Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
Operating Income
$12.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$3.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Operating Income
$22m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-25%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Operating Income
₪40m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$15.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Income
₪5.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-10%
|
See Also
What is Redhill Biopharma Ltd's Operating Income?
Operating Income
12.6m
USD
Based on the financial report for Dec 31, 2023, Redhill Biopharma Ltd's Operating Income amounts to 12.6m USD.